Drug intelligence / Profile preview

Polysulfated glycosaminoglycan

Development stage: Unknown
Lead developer: American Regent
Administration: Injectable

Overview

Polysulfated glycosaminoglycan (PSGAG) is an FDA-approved injectable pharmaceutical drug primarily used for joint health in horses and dogs. It serves as the active pharmaceutical ingredient (API) for products like Adequan. The drug is manufactured by companies such as American Regent, which acquired the API manufacturing plant from Daiichi Sankyo Altkirch SARL to enhance production capacity and secure the supply chain due to increasing demand in the animal health sector.

Brand names: Adequan
Other names: PSGAG

Targets

Neuraminidase

Beyond the preview

Go deeper on Polysulfated glycosaminoglycan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polysulfated glycosaminoglycan.

Explore the full profile